Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma Journal Article


Authors: Inda, M. D. M.; Bonavia, R.; Mukasa, A.; Narita, Y.; Sah, D. W. Y.; Vandenberg, S.; Brennan, C.; Johns, T. G.; Bachoo, R.; Hadwiger, P.; Tan, P.; DePinho, R. A.; Cavenee, W.; Furnari, F.
Article Title: Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
Abstract: Human solid tumors frequently have pronounced heterogeneity of both neoplastic and normal cells on the histological, genetic, and gene expression levels. While current efforts are focused on understanding heterotypic interactions between tumor cells and surrounding normal cells, much less is known about the interactions between and among heterogeneous tumor cells within a neoplasm. In glioblastoma multiforme (GBM), epidermal growth factor receptor gene (EGFR) amplification and mutation (EGFRvIII/ΔEGFR) are signature pathogenetic events that are invariably expressed in a heterogeneous manner. Strikingly, despite its greater biological activity than wild-type EGFR (wtEGFR), individual GBM tumors expressing both amplified receptors typically express wtEGFR in far greater abundance than the ΔEGFR lesion. We hypothesized that the minor ΔEGFR-expressing subpopulation enhances tumorigenicity of the entire tumor cell population, and thereby maintains heterogeneity of expression of the two receptor forms in different cells. Using mixtures of glioma cells as well as immortalized murine astrocytes, we demonstrate that a paracrine mechanism driven by ΔEGFR is the primary means for recruiting wtEGFR-expressing cells into accelerated proliferation in vivo. We determined that human glioma tissues, glioma cell lines, glioma stem cells, and immortalized mouse Ink4a/Arf-/- astrocytes that express ΔEGFR each also express IL-6 and/or leukemia inhibitory factor (LIF) cytokines. These cytokines activate gp130, which in turn activates wtEGFR in neighboring cells, leading to enhanced rates of tumor growth. Ablating IL-6, LIF, or gp130 uncouples this cellular cross-talk, and potently attenuates tumor growth enhancement. These findings support the view that a minor tumor cell population can potently drive accelerated growth of the entire tumor mass, and thereby actively maintain tumor cell heterogeneity within a tumor mass. Such interactions between genetically dissimilar cancer cells could provide novel points of therapeutic intervention. © 2010 by Cold Spring Harbor Laboratory Press.
Keywords: controlled study; human tissue; gene mutation; human cell; mutation; pathogenesis; erlotinib; nonhuman; glioma; mutant protein; cell proliferation; animal cell; mouse; animals; mice; animal tissue; cell survival; gene amplification; gene expression; epidermal growth factor receptor; astrocyte; in vivo study; receptor, epidermal growth factor; cell population; cell line, tumor; wild type; stem cell; gene expression regulation, neoplastic; cytokine; cytokines; biological activity; mice, nude; neoplastic stem cells; glioma cell; glioblastoma; carcinogenicity; gefitinib; tumor cell; murinae; interleukin 6; interleukin-6; ligands; cytokine receptor gp130; egfr; up-regulation; tumor growth; cell interaction; protein cross linking; mutant; competitive inhibition; Δegfr; gp130; il-6; lif; tumor heterogeneity; glycoprotein gp 130; leukemia inhibitory factor; cell immortalization
Journal Title: Genes and Development
Volume: 24
Issue: 16
ISSN: 0890-9369
Publisher: Cold Spring Harbor Laboratory Press  
Date Published: 2010-08-15
Start Page: 1731
End Page: 1745
Language: English
DOI: 10.1101/gad.1890510
PUBMED: 20713517
PROVIDER: scopus
PMCID: PMC2922502
DOI/URL:
Notes: --- - "Cited By (since 1996): 6" - "Export Date: 20 April 2011" - "CODEN: GEDEE" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Cameron Brennan
    226 Brennan